Immunomedics makes $10 million placement

Article

Monoclonal antibody imaging agent developer Immunomedics of MorrisPlains, NJ, announced last week that it has sold $10 million inconvertible preferred stock to international investors. The investorscan convert the stock into shares of common stock over

Monoclonal antibody imaging agent developer Immunomedics of Morris

Plains, NJ, announced last week that it has sold $10 million in

convertible preferred stock to international investors. The investors

can convert the stock into shares of common stock over the next

two years.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Reducing Mammography Workload by Nearly 40 Percent? What a New Hybrid AI Study Reveals
 What New Research Reveals About Portable Low-Field MRI and Patients with Suspected Alzheimer’s Disease
Diagnostic Imaging's Weekly Scan: August 11 — August 17 (Video Version)
© 2025 MJH Life Sciences

All rights reserved.